In other words, you're getting a better deal for patients while under the part D program. PBMs drive up the cost for seniors and taxpayers. So to you, how does the cost plus drug company achieve these lower prices and what barriers does a company face when entering or expanding in the prescription drug market? (02:43–02:47)
STATEMENT
Asserts that PBMs increase costs for seniors and taxpayers.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.